Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MedImmune Studying FluMist’s Power Against Drifted Strains

  • News

Executive Summary

MedImmune is conducting studies to see if FluMist provides immunization beyond strains included in the vaccine

You may also be interested in...



Flu Vaccine Efficacy Is Too Low To “Sell,” CDC Says; Firms Want More Demand

More efficacious influenza vaccines must be developed in order to encourage use, Centers for Disease Control & Prevention Smallpox Preparedness & Response Activity Director Ray Strikas, MD, said

Flu Vaccine Efficacy Is Too Low To “Sell,” CDC Says; Firms Want More Demand

More efficacious influenza vaccines must be developed in order to encourage use, Centers for Disease Control & Prevention Smallpox Preparedness & Response Activity Director Ray Strikas, MD, said

FluMist Picks Up Insurance Reimbursement, CDC Endorsement After Outbreak

MedImmune/Wyeth's FluMist has picked up insurance company support with a series of announcements from payors that they will reimburse members receiving FluMist vaccines

Table

View full table

Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS042994

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By